ENTITY
BeiGene

BeiGene (6160 HK)

439
Analysis
Health CareChina
BeiGene, Ltd. operates as a commercial stage biopharmaceutical company. The Company focuses on discovery, development, and commercialization of molecularly targeted and immuno-oncology drugs for the treatment of cancer. BeiGene serves patients worldwide.
more
22 Dec 2024 06:30

Last Week In Event SPACE: Seven & I, CPMC, UBTech Robotics, Macromill, 2024 Best-Of

It’s Sunday! Pour yourself a coffee, grab a comfortable seat, and sift through a brief summary of insights on various events discussed during the...

Logo
524 Views
Share
bullishBeiGene
17 Dec 2024 10:21

HK CEO & Director Dealings (17th Dec 2024): BeiGene, China Wantian, Super Hi Int'l/Haidilao

The data in this insight is collated from the "shareholding disclosure" link on the HKEx website.  These insights also flag those companies where...

Logo
376 Views
Share
15 Dec 2024 10:05

A-H Premium Weekly (Dec 13th):ZOOMLION, QDP, BeiGene, INNOCARE, TEC, MA STEEL, AIR CHINA

We analyzed A-H premium changes in the past week and highlight A-H premium changes for ZOOMLION, QDP, BeiGene, INNOCARE, TEC, MA STEEL, AIR CHINA.

Logo
341 Views
Share
15 Dec 2024 07:30

APAC Healthcare Weekly (Dec 15)-Daiichi Sankyo, Eisai, Celltrion, Metropolis Healthcare, CSPC Pharma

The insight covers key developments in prominent APAC healthcare companies. These developments are expected to impact the financials of the...

Logo
481 Views
Share
15 Dec 2024 06:02

Quiddity Leaderboard HSCEI Mar 25: One Change Likely but More Names Lurking Close to the Border

The Expected ADD China Resources Power (836 HK) could see 0.9x ADV index buying and the Expected DEL Li Ning (2331 HK) could see 0.6x ADV of index...

Share
x